|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Is there a role of lipid-lowering therapies in the management of fatty liver disease?显示文摘Atherogenic dyslipidemia is characterized by increased triglyceride-rich lipoproteins and low high-density lipoprotein cholesterol concentrations.It is highly prevalent in non-alcoholic fatty liver disease(NAFLD)and contributes to the increased cardiovascular risk associated with this condition.Alongside insulin resistance it plays an important pathogenetic role in NAFLD/non-alcoholic steatohepatitis(NASH)development and progression.It has been shown that cholesterol-lowering reduces cardiovascular risk more in NAFLD vs non-NAFLD high-risk individuals.This evidence highlights the importance of effective lipid modulation in NAFLD.In this narrative review the effects of the most commonly used lipid-lowering therapies on liver outcomes alongside their therapeutic implications in NAFLD/NASH are critically discussed.Preclinical and clinical evidence suggests that statins reduce hepatic steatosis,inflammation and fibrosis in patients with NAFLD/NASH.Most data are derived from observational and small prospective clinical studies using changes in liver enzyme activities,steatosis/fibrosis scores,and imaging evidence of steatosis as surrogates.Also,relevant histologic benefits were noted in small biopsy studies.Atorvastatin and rosuvastatin showed greater benefits,whereas data for other statins are scarce and sometimes conflicting.Similar studies to those of statins showed efficacy of ezetimibe against hepatic steatosis.However,no significant anti-inflammatory and anti-fibrotic actions of ezetimibe have been shown.Preclinical studies showed that fibrates through peroxisome proliferator-activated receptor(PPAR)αactivation may have a role in NAFLD prevention and management.Nevertheless,no relevant benefits have been noted in human studies.Species-related differences in PPARαexpression and its activation responsiveness may help explain this discrepancy.Omega-3 fatty acids reduced hepatic steatosis in numerous heterogeneous studies,but their benefits on hepatic inflammation and fibrosis have not been established.Promising preliminary data for the highly purified eicosapentaenoic acid require further confirmation.Observational studies suggest that proprotein convertase subtilisin/kexin9 inhibitors may also have a role in the management of NAFLD,though this needs to be established by future prospective studies. | Ismini Tzanaki Aris P Agouridis Michael S Kostapanos | 2022 | World Journal of Hepatology2022，14，1： | 2 |
| 2 | Rosuvas- tatin treatment is associat-es with an increase in insulin resist- ance in hyperlipidaemie patients with impared fasting glucose 显示文摘 | Kostapanos MS Milionis HJ Agouridis AD | 2009 | In J Clin Pract2009，63，9： | 1 |
| 3 | The effect of statin therapy on arterial stiffness by measuring pulse wave velocity:a systematic review显示文摘 | Rizos EC Agouridis AP Elisaf MS | 2010 | Curr Vasc Pharmacol2010，8，5： | 1 |
| 4 | Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose显示文摘 | Kostapanos MS Milionis HJ Agouridis AD | | 0，，09： | 1 |
| 5 | High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia显示文摘 | Agouridis AP Tsimihodimos V Filippatos TD | 2011 | Lipids2011，46，6： | 1 |
| 6 | The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia显示文摘 | Aris P Agouridis Vasilis Tsimihodimos Theodosios D Filippatos Andromachi A Dimitriou Costantinos C Tellis Moses S Elisaf Dimitri P Mikhailidis Alexandros D Tselepis | 2011 | Expert Opinion on Pharmacotherapy2011，，17： | 1 |
| 7 | Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?显示文摘 | Agouridis AP Rizos CV Elisaf MS | 2013 | Rev Diabet Stud2013，10，23： | 1 |
| 8 | Comparative study of spent grains and delignified spent grains as yeast supports for alcohol production from molasses显示文摘 | Kopsahelis N Agouridis N Bekatrou A | | 0，，7： | 1 |
| 9 | All for statins and statins for all: an update显示文摘 | Agouridis P Aris S Moses R | 2016 | Curt Pharm Des2016，22，1： | 1 |
| 10 | Rosuvastatin treatment is associated with an increase in insulin tresistance in hyperlipidaemic patients with impaired fasting glucose 显示文摘 | Kostapanos MS Milionis HJ Agouridis AD | 2009 | lnt J Clin Pract2009，63，9： | 1 |
| 11 | The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a system- atic review显示文摘 | Rizos EC Agouridis AP Elisaf MS | 2010 | Curr Vasc Pharmacol2010，8，5： | 1 |
| 12 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω‐3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome显示文摘 | A. P. Agouridis M. S. Kostapanos V. Tsimihodimos C. Kostara D. P. Mikhailidis E. T. Bairaktari A. D. Tselepis M. S. Elisaf | 2012 | International Journal of Clinical Practice2012，，9： | 1 |
| 13 | The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients显示文摘 | E. S. Nakou T. D. Filippatos A. P. Agouridis C. Kostara E. T. Bairaktari M. S. Elisaf | 2010 | Lipids2010，，5： | 1 |
| 14 | Epicardial adipose tissue deposition in patients with diabetes and renal impairment: Analysis of the literature显示文摘Diabetes mellitus(DM)is defined as a chronic disease of disordered metabolism with an ongoing increase in prevalence and incidence rates.Renal disease in patients with diabetes is associated with increased morbidity and premature mortality,particularly attributed to their very high cardiovascular risk.Since this group of patients frequently lacks specific symptomatology prior to the adverse events,a screening tool for the identification of high-risk patients is necessary.The epicardial adipose tissue(EAT)is a biologically active organ having properties similar to visceral adipose tissue and has been associated with metabolic diseases and coronary artery disease.Superior to conventional cardiovascular risk factors and anthropometric measures,including body mass index and waist circumference,the EAT can early predict the development of coronary artery disease.Assessment of EAT can be performed by twodimensional echocardiography,magnetic resonance imaging or computer tomography.However,its role and significance in patients with DM and nephropathy has not been thoroughly evaluated.The aim of the current editorial is to evaluate all available evidence regarding EAT in patients with DM and renal impairment.Systematic search of the literature revealed that patients with DM and nephropathy have increased EAT measurements,uncontrolled underlying disease,high body mass index and raised cardiovascular risk markers.Acknowledging the practical implications of this test,EAT assessment could serve as a novel and non-invasive biomarker to identify high-risk patients for cardiovascular adverse events. | Zoi Kleinaki Aris P Agouridis Maria Zafeiri Theodoros Xanthos Constantinos Tsioutis | 2020 | World Journal of Diabetes2020，11，2： | 1 |
| 15 | Comparative study of spent grains and delignified spent grains as yeast supports for alcohol production from molasses显示文摘 | KOPSAHELIS N AGOURIDIS N BEKATROU A | 2007 | Bioresouree Technol2007，98，7： | 1 |
| 16 | Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome显示文摘 | Agouridis AP Kostapanos MS Tsimihodimos V | 2012 | Int J Clin Pract2012，66，9： | 1 |
| 17 | Rosuvas tatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose 显示文摘 | Kostapanos MS Milionis HJ Agouridis AD | 2009 | Int J Clin Pract2009，63，9： | 1 |
| 18 | Compara- tive study of spent grains and delignified spent grains as yeast supports for alcohol production from molasses 显示文摘 | KOPSAHELIS N AGOURIDIS N BEKATOROU A | 2007 | Bioresource Teehnoi2007，98，7： | 1 |
| 19 | Aliskiren in patients with diabetes: a systematic review显示文摘 | Rizos EC Agouridis AP Elisaf MS | 2012 | Curr Vase Pharmacol2012，10，2： | 1 |
| 20 | Aliskiren in patients with diabetes: a systematic review显示文摘 | Rizos EC Agouridis AP Elisaf MS | 2012 | Curr Vase Pharmacol2012，10，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员